mProX™ Human NEK3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX400	Magic™ Human NEK3 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;T47D;MDA-MB-231

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research;Metabolic Research

Related Diseases

Glycogen Storage Disease Ia; Glycogen Storage Disease

Gene ID

Human:4752

UniProt ID

Human:P51956

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NEK3, a member of the NEK (Never in mitosis A related kinase) gene family, has been found to have differential expression in various types of cancers. In esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE), NEK3 is significantly upregulated, suggesting its potential role in tumorigenesis and progression of EAC. In prostate cancer, BRCA2-deficient tumors exhibit enriched homozygous deletions at NEK3, indicating its involvement in the etiology and prognosis of BRCA2-deficient prostate tumors. In breast cancer, different NEK family members show distinct expression patterns and prognostic values. NEK2, NEK6, and NEK11 are significantly highly expressed in breast cancer, while NEK1, NEK3, NEK8, NEK9, NEK10, and NEK11 are associated with better prognosis. NEKs have also been explored as potential biomarkers for cancer and as therapeutic targets, with some NEK inhibitors reported in the literature. Additionally, NEKs, including NEK2, NEK3, NEK4, NEK7, and NEK9, have been induced in the lungs of mice with sepsis, suggesting their involvement in inflammatory processes and potential as therapeutic targets for conditions such as acute respiratory distress syndrome (ARDS) and sepsis. Overall, NEK3 and other NEK family members have emerged as important players in cancer development, prognosis, and potential therapeutic interventions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NEK3 Stable Cell Line (S01YF-1023-PY25). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Jones (Verified Customer)

What are the implications of biallelic loss of function mutations in NEK3? Nov 28 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Biallelic loss of function mutations in NEK3 can lead to cilia-related abnormal cardiac left-right patterning, including situs inversus and heterotaxy. Nov 28 2022

chat Skyler Smith (Verified Customer)

How does NEK3 differ from other NIMA family members in its function? Nov 08 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Unlike most NIMA family members, NEK3 inhibition does not affect cell cycle progression. It also plays a role in cancer progression and is associated with breast cancer motility and cell migration. Nov 08 2020

Published Data

Fig.1 Knockdown of NEK3 in human breast cancer cell lines.

T47D and MDA-MB231 cells underwent transfection with either control or Nek3 siRNA. Subsequently, Western blot analysis was conducted on whole-cell lysates (WCL) 72 hours post-transfection to ascertain the levels of total Nek3 (upper portion of the blots) and actin (lower portion). Quantitative assessment of Nek3 and actin expression was performed using densitometry, with Nek3 expression being normalized relative to actin levels (above the blot images).

Ref: Miller, S. L., et al. "Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells." Oncogene 26.32 (2007): 4668-4678.

Pubmed: 17297458

DOI: 10.1038/sj.onc.1210264

Research Highlights

Chen, Lei. et al. "Differential Expression of NEK Kinase Family Members in Esophageal Adenocarcinoma and Barrett's Esophagus." Cancers, 2023.
The incidence of esophageal adenocarcinoma (EAC) has greatly increased in the past four decades, making it the most prevalent form of esophageal cancer in the United States and Western countries. The NEK (Never in mitosis A (NIMA) related kinase) gene family consists of 11 serine/threonine kinases and has been found to be abnormally expressed in various human cancers, playing a significant role in tumor growth, advancement, and drug resistance. However, the expression of NEKs in EAC and its pre-cancerous state, Barrett's esophagus (BE), has not yet been studied. In this study, the authors analyzed data from the TCGA and 9 GEO databases, including 10 datasets (8 of which contained EAC and 6 contained BE), to investigate NEK expression in EAC and BE. The results revealed a significant upregulation of NEK2 (7/8), NEK3 (6/8), and NEK6 (6/8) in EAC compared to normal esophagus samples, while NEK1 was downregulated. However, genomic alterations of these NEKs were not frequently observed in EAC. These findings were validated through qRT-PCR analysis of EAC cell lines, Western blotting, and immunohistochemistry and immunofluorescence of primary EAC tissues. The results suggest that NEK2, NEK3, and NEK7 may play a crucial role in EAC development due to their frequent upregulation.
Chen, Lei. et al. "Differential Expression of NEK Kinase Family Members in Esophageal Adenocarcinoma and Barrett's Esophagus." Cancers, 2023.
Pubmed: 37835513 DOI: 10.3390/cancers15194821

H Kensler, Kevin. et al. "The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer." NPJ precision oncology, 2022.
Individuals carrying germline BRCA2 pathogenic sequence variants are at an increased risk for aggressive prostate cancer and may benefit from precision oncology treatments. The researchers investigated whether prostate cancers with BRCA2 deficiency (BRCA2D) display distinct clinicopathological characteristics.
H Kensler, Kevin. et al. "The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer." NPJ precision oncology, 2022.
Pubmed: 35715489 DOI: 10.1038/s41698-022-00284-6